Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (926) Arrow Down
Filter Results: (926) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (926)
    • People  (2)
    • News  (70)
    • Research  (778)
    • Events  (1)
    • Multimedia  (2)
  • Faculty Publications  (668)

Show Results For

  • All HBS Web  (926)
    • People  (2)
    • News  (70)
    • Research  (778)
    • Events  (1)
    • Multimedia  (2)
  • Faculty Publications  (668)
← Page 39 of 926 Results →
  • March 1993
  • Supplement

Burroughs Wellcome and AZT (B)

By: Willis M. Emmons III
Describes Burroughs Wellcome's response to protests over the pricing of its AIDS drug AZT in September 1989. Also presents short-term reactions by government officials, AIDS activists, and investors to Burroughs Wellcome's strategy. View Details
Keywords: Ethics; Health Pandemics; Multinational Firms and Management; Price; Crime and Corruption; Risk and Uncertainty; Business Strategy; Business and Community Relations; Business and Government Relations; Business and Shareholder Relations; Pharmaceutical Industry
Citation
Purchase
Related
Emmons, Willis M., III. "Burroughs Wellcome and AZT (B)." Harvard Business School Supplement 793-114, March 1993.
  • March 1997
  • Teaching Note

Eli Lilly and Company: Innovation in Diabetes Care TN

By: Clayton M. Christensen and Bret J. Baird
Teaching Note for (9-696-077). View Details
Keywords: Pharmaceutical Industry
Citation
Purchase
Related
Christensen, Clayton M., and Bret J. Baird. "Eli Lilly and Company: Innovation in Diabetes Care TN." Harvard Business School Teaching Note 697-101, March 1997.
  • December 1998 (Revised September 1999)
  • Case

Novartis: Betting on Life Sciences

By: Ray A. Goldberg, Carin-Isabel Knoop and Srinivas Sunder
The merger of Ciba-Geigy and Sandoz produced genomic-based synergies for health care, agribusiness, and nutritional supplements. How to build on the strength of the individual divisions and provide synergies that would continue Novartis' leadership role is the question... View Details
Keywords: Mergers and Acquisitions; Business Divisions; Health Care and Treatment; Leadership; Product Positioning; Science-Based Business; Corporate Strategy; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Goldberg, Ray A., Carin-Isabel Knoop, and Srinivas Sunder. "Novartis: Betting on Life Sciences." Harvard Business School Case 599-076, December 1998. (Revised September 1999.)
  • January–February 1994
  • Article

Financial Engineering at Merck

By: Timothy A. Luehrman
Keywords: Finance; Engineering; Health; Pharmaceutical Industry
Citation
Find at Harvard
Related
Luehrman, Timothy A. "Financial Engineering at Merck." Harvard Business Review 72, no. 1 (January–February 1994): 89–99.
  • November 18 2004
  • Article

Merck's Recall of Rofecoxib: A Strategic Perspective

By: Felix Oberholzer-Gee and Noorein Inamdar
Keywords: Health; Perspective; Pharmaceutical Industry
Citation
Find at Harvard
Related
Oberholzer-Gee, Felix, and Noorein Inamdar. "Merck's Recall of Rofecoxib: A Strategic Perspective." New England Journal of Medicine 351, no. 21 (November 18 2004): 2147–2149.
  • April 1999 (Revised May 2000)
  • Case

Pilgrim Drug Company

David Thomas takes his first sales management assignment and is faced with a sales rep revolt because of a possible territory reorganization. In addition, his sales division is performing well below the national average. Rewritten version of an earlier case. View Details
Keywords: Conflict Management; Salesforce Management; Performance; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Burton, M. Diane, and Jeffrey L. Bradach. "Pilgrim Drug Company." Harvard Business School Case 499-062, April 1999. (Revised May 2000.)
  • February 26, 2003
  • Article

Consumers' Reports on the Health Effects of Direct-To-Consumer Drug Advertising

By: Joel S. Weissman, David Blumenthal, Alvin J. Silk, Kinga Zapert, Michael Newman and Robert Leitman
Keywords: Customers; Advertising; Health; Pharmaceutical Industry
Citation
Find at Harvard
Read Now
Related
Weissman, Joel S., David Blumenthal, Alvin J. Silk, Kinga Zapert, Michael Newman, and Robert Leitman. "Consumers' Reports on the Health Effects of Direct-To-Consumer Drug Advertising." Health Affairs (February 26, 2003).
  • 06 Mar 2012
  • First Look

First Look: March 6

influential, and industry less influential, than we commonly assume. How Early Adoption Has Increased Wealth—Until Now Authors:Diego Comin and Bart Hobijn Publication:Harvard Business Review 90, no. 3 (March 2012) Abstract Societies that... View Details
Keywords: Sean Silverthorne
  • 04 Apr 2022
  • Research & Ideas

Tech Hubs: How Software Brought Talent and Prosperity to New Cities

period. Software is penetrating other industries, Kerr notes. Take vaccines. Pharmaceutical companies’ speedy development of mRNA-based vaccines for COVID-19 required software, he notes. “Their capacity to bring a substantial software, AI... View Details
Keywords: by Rachel Layne
  • 30 Apr 2001
  • Research & Ideas

Entering the Age of Alliances

competencies of each partner and create two-way value is evidenced by, among others, the collaboration between The College Fund (UNCF) and Merck. UNCF, the largest and oldest minority educational assistance organization in the United States, and Merck, a leading global... View Details
Keywords: by James Austin
  • 17 Sep 2001
  • Research & Ideas

Why E-commerce Didn’t Die With the Fall of Webvan

intimacy, and community offered by direct-to-consumer marketing will have an impact on every industry and intermediary," Deighton predicted. Supermarkets may have "dodged a bullet" for now, but direct-to-consumer marketing... View Details
Keywords: by Martha Lagace; Consumer Products; Retail
  • 09 Jan 2007
  • First Look

First Look: January 9, 2007

Communications Equipment Industry Harvard Business School Case 107-025 Purchase this case: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=107025 Symantec vs. McAfee: Competing in the Consumer Anti-virus View Details
Keywords: Martha Lagace
  • Research Summary

Overview

I am interested in the individual experience of learning in organizational settings, particularly how employees learn to learn from the challenging work they do. I am currently researching the role of reflection for raising awareness of learning opportunities that... View Details
Keywords: Learning; Learning And Development; Learning Organizations; Intrinsic Motivation; Reflection; Goal Setting; Performance Measurement; Innovation; Job Design; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry
  • January 2023
  • Teaching Note

The Opioid Settlement and Executive Pay at AmerisourceBergen

By: Suraj Srinivasan and Li-Kuan Ni
Teaching Note for HBS Case No 122-014. In 2020, AmerisourceBergen Corporation, a Fortune 50 company in the drug distribution industry, agreed to settle thousands of lawsuits filed nationwide against the company for its opioid distribution practices that critics alleged... View Details
Keywords: Opioids; Shareholder Activism; Investment Activism; Corporate Accountability; Corporate Governance; Governance Compliance; Governance Controls; Executive Compensation; Risk Management; Corporate Social Responsibility and Impact; Business and Shareholder Relations; Business and Stakeholder Relations; Distribution Industry; Distribution Industry; Distribution Industry; United States; West Virginia; Tennessee; Ohio; Pennsylvania
Citation
Purchase
Related
Srinivasan, Suraj, and Li-Kuan Ni. "The Opioid Settlement and Executive Pay at AmerisourceBergen." Harvard Business School Teaching Note 123-067, January 2023.
  • Article

Internal Deadlines, Drug Approvals, and Safety Problems

By: Lauren Cohen, Umit Gurun and Danielle Li
Absent explicit quotas, incentives, reporting, or fiscal year-end motives, drug approvals around the world surge in December, at month-ends, and before respective major national holidays. Drugs approved before these informal deadlines are associated with significantly... View Details
Keywords: Health; Economics; Government and Politics; Innovation and Invention; Research; Science; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry
Citation
SSRN
Find at Harvard
Related
Cohen, Lauren, Umit Gurun, and Danielle Li. "Internal Deadlines, Drug Approvals, and Safety Problems." American Economic Review: Insights 3, no. 1 (March 2021): 67–82.
  • September 2019
  • Case

Bill & Melinda Gates Foundation: Shaping the Vaccine Manufacturing Ecosystem

By: Willy C. Shih
Vaccines for children has been a long-standing focus for the Bill & Melinda Gates Foundation, and its critical role in public health made its production an important economic and political issue. This case describes the Foundation's investment in a breakthrough vaccine... View Details
Keywords: Vaccine; Production; Supply Chain; Product; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Belgium
Citation
Educators
Purchase
Related
Shih, Willy C. "Bill & Melinda Gates Foundation: Shaping the Vaccine Manufacturing Ecosystem." Harvard Business School Case 620-021, September 2019.
  • March 2010 (Revised May 2012)
  • Case

Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration

By: Karim R. Lakhani and Paul R. Carlile
This case presents the Myelin Repair Foundation's accelerated research collaboration model for drug discovery. It highlights the challenges of building a multi-disciplinary and multi-institutional research collaboration that is attempting to create a treatment for... View Details
Keywords: Research and Development; Intellectual Property; Risk and Uncertainty; Strategic Planning; Collaborative Innovation and Invention; Health Disorders; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Lakhani, Karim R., and Paul R. Carlile. "Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration." Harvard Business School Case 610-074, March 2010. (Revised May 2012.)
  • 24 Jan 2012
  • First Look

First Look: Jan. 24

This chapter proposes a new lens to understand corruption, using internal records collected from firms that pay bribes. We examine widespread corruption in three industries in an Asian developing country: procurement, View Details
Keywords: Sean Silverthorne
  • February 1999
  • Teaching Note

Wegmans Food Markets: Diabetes Counseling TN

By: David E. Bell
Teaching Note for (9-599-057). View Details
Keywords: Pharmaceutical Industry; Pharmaceutical Industry
Citation
Purchase
Related
Bell, David E. "Wegmans Food Markets: Diabetes Counseling TN." Harvard Business School Teaching Note 599-100, February 1999.
  • 03 Jan 2017
  • First Look

January 3, 2017

January 2017 Journal of Financial Economics The Unintended Consequences of the Zero Lower Bound Policy By: Di Maggio, Marco, and Marcin Kacperczyk Abstract—We study the impact of the zero lower bound interest rate policy on the industrial... View Details
Keywords: Carmen Nobel
  • ←
  • 39
  • 40
  • …
  • 46
  • 47
  • →
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.